MUL 1867

Drug Profile

MUL 1867

Alternative Names: MUL-1867-CF

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TGV-Laboratories
  • Developer TGV Therapeutics; TGV-Laboratories
  • Class Antibacterials; Antibronchitics; Hydrazines
  • Mechanism of Action Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gingivitis; Periodontitis
  • Clinical Phase Unknown Chronic obstructive pulmonary disease; Cystic fibrosis; Pneumonia
  • Preclinical Burn infections; Conjunctivitis; Diabetic foot ulcer; Emphysema; Lung disorders; Skin and soft tissue infections; Vaginitis
  • Research Nosocomial pneumonia

Most Recent Events

  • 12 Apr 2016 MUL 1867 receives Orphan Drug status for Cystic fibrosis in USA
  • 02 Nov 2015 Clinical trials in Pneumonia in Russia (Inhalation)
  • 31 Oct 2015 Early research in Nosocomial pneumonia in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top